JAK inhibitors should be an option for symptomatic myelofibrosis patients even if their disease is low risk, according to new guidelines from the American Society of Hematology (ASH). Published in ...

A joint clinical practice guideline recommends novel peroxisome proliferator-activated receptor agonists as second-line therapy for patients with primary biliary cholangitis, along with a new therapy ...

The addition of the bispecific T-cell engager tarlatamab to durvalumab as first-line maintenance therapy significantly improves survival in patients with extensive-stage small-cell lung cancer (SCLC).

New US guidelines for the treatment of hidradenitis suppurativa have endorsed the use of biologics adalimumab, bimekizumab, infliximab, and secukinumab while also centring supportive pain management ...

PCOS is likely to need another rebrand in the near future because its new name, PMOS, is scientifically inaccurate, it is being argued. A debate over the future name of polycystic ovary syndrome has ...

SGLT2 inhibitor use in patients with cardiovascular disease, diabetes, heart failure, and/or chronic kidney disease is associated with small but statistically significant and consistent increases in ...

Trials of agents for the management of IgA nephropathy dominated the American Society of Nephrology’s 2026 Kidney Week, including three featured as high-impact trials in the opening plenary and four ...

The investigational weight-loss drug retatrutide cut sleep apnoea events by 25 to 34 an hour at its two highest doses, versus about 10 with placebo, in two industry-funded phase 3 trials. The ...

There may be more than one way to successfully come off long-term proton pump inhibitors, with a trial comparing three deprescribing strategies finding almost half of patients substantially stopped ...

CAR T-cell therapy can be considered for patients with severe refractory neurological autoimmune disease, according to updated expert consensus advice. Where possible, this should be delivered as part ...

Lecanemab causes measurable and variable changes in plasma biomarkers that could potentially guide treatment and inform prognosis, new research suggests. The single-centre US study found that p-tau ...